Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
HOME > COLUMN
COLUMN
-
3 Strategies for Attracting Talent Who Aren’t Looking for a Job
October 18, 2023
-
How Can You Improve Field Force Productivity in the Age of Digital? Omnichannel Excellence and the Importance of a Strong “Middle Layer”
October 6, 2023
-
How to Get 4 Qualified Candidates within 4 Weeks
September 25, 2023
-
How Far Has Your Organization Come? Key Lessons Learned from Ongoing Commercial Transformations in Japan
September 11, 2023
-
Mission Impossible: Finding the Right Leader to Launch a Disruptive Medical Technology into Japan
August 10, 2023
-
How Healthcare Companies Should Hire in the Post-COVID Work Environment
July 19, 2023
-
The Impact of a Shrinking Labor Market on the Healthcare Industry
June 23, 2023
-
Seven Recruitment Trends in 2023
May 31, 2023
-
The Inflation Reduction Act - Implications for Japanese Pharmaceutical Manufacturers
May 19, 2023
-
How to Serve and Get Ahead
April 21, 2023
-
The Increasing Impact of Real-World Evidence
March 31, 2023
-
Rewarding Value and Innovation and Ensuring Financial Viability of the Biopharmaceutical Supply Chain in Japan
March 16, 2023
-
Why Market Mapping Is Critical to Your Organization
February 24, 2023
-
When It Comes to Recruitment, Time Is Money. Have a Plan!
January 31, 2023
-
Cell Therapy in Japan: A Potentially Attractive Market at a Turning Point Facing Challenges
December 16, 2022
-
How to Succeed in Bad Times and Good
December 9, 2022
-
The Pros and Cons of Working from Home in 2022
November 25, 2022
-
Rare Diseases in Japan: Moving from Treatment to Integrated Care
October 27, 2022
-
The Evolving US Managed Care Environment and Implications of US Market Attractiveness for Japanese Manufacturers
September 5, 2022
-
Fairness, Not Diversity
August 26, 2022
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…